MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Down 11.6% in March

MiNK Therapeutics, Inc. (NASDAQ:INKT) saw a large decrease in short interest in March. As of March 31st, there was short interest totalling 41,100 shares, a decrease of 11.6% from the March 15th total of 46,500 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average daily volume of 99,400 shares, the short-interest ratio is currently 0.4 days.

MiNK Therapeutics Trading Down 7.7 %

INKT opened at $0.91 on Tuesday. MiNK Therapeutics has a 12 month low of $0.75 and a 12 month high of $3.34. The business’s 50-day moving average price is $0.96 and its 200-day moving average price is $1.00. The company has a market cap of $31.52 million, a P/E ratio of -1.38 and a beta of 0.13.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Equities research analysts forecast that MiNK Therapeutics will post -0.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their target price on shares of MiNK Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, March 21st.

Institutional Investors Weigh In On MiNK Therapeutics

A number of institutional investors have recently modified their holdings of INKT. Vanguard Group Inc. purchased a new stake in MiNK Therapeutics during the 3rd quarter valued at about $104,000. Longbow Finance SA bought a new stake in MiNK Therapeutics in the 4th quarter worth about $435,000. Millennium Management LLC purchased a new position in MiNK Therapeutics in the 4th quarter worth about $28,000. Geode Capital Management LLC boosted its holdings in shares of MiNK Therapeutics by 266.6% during the 2nd quarter. Geode Capital Management LLC now owns 92,723 shares of the company’s stock valued at $195,000 after acquiring an additional 67,428 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of MiNK Therapeutics by 655.6% in the second quarter. BlackRock Inc. now owns 82,029 shares of the company’s stock worth $172,000 after acquiring an additional 71,173 shares during the period. 2.87% of the stock is owned by hedge funds and other institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.